查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602405

爱迪生氏症药物市场：按药物类别、诊断、治疗方法、通路、给药途径分类 - 2025-2030 年全球预测

Addison's Disease Treatment Market by Drug Class (Glucocorticoid, Mineralocorticoid), Diagnosis (Imaging Testing, Laboratory Testing), Treatments, Distribution Channel, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

爱迪生氏症治疗药物市场2023年估值为14.1亿美元，预计2024年将达到15.4亿美元，复合年增长率为10.72%，预计到2030年将达到28.8亿美元。

爱迪生氏症是一种罕见的内分泌疾病，其特征是肾上腺产生荷尔蒙的缺陷，为药物治疗创造了一个利基但重要的市场。由于这种疾病的慢性性质以及荷尔蒙补充疗法在预防危及生命的肾上腺危象方面的重要作用，因此需要有效的治疗。目前，主要用途是皮​​肤类固醇和盐皮质激素替代疗法，由于患者意识的提高和远距远端医疗的进步，最终用途在医院、专科诊所和居家医疗环境中获得了显着的吸引力。肾上腺功能不全疾病盛行率上升、诊断技术的改进以及高风险老年人口的增加等因素推动了市场成长。有开发新型递送机制的机会，例如植入式装置和缓释性，以提高患者的依从性和生活品质。此外，基因治疗和生物治疗的研究正在取得进展，有潜力提供差异化治疗。然而，限制因素包括高昂的研发成本、长期使用类固醇的潜在副作用，以及减缓新产品进入的严格监管核准流程。此外，提高医疗专业人员的意识提升，提高早期诊断和治疗的准确性也是一个问题。使用基因检测和人工智慧驱动的患者管理系统的个人化医疗创新有可能显着改善治疗结果和市场定位。对于业务成长，与研究机构的策略联盟以及对生物资讯学的投资可以提供竞争优势。作为一个竞争激烈且高度专业化的市场，成功需要科学的专业知识和以患者为中心的方法。实施数位医疗解决方案和促进强有力的病患教育倡议是应对不断变化的情况和利用新机会的策略措施。

主要市场统计
基准年[2023] 14.1亿美元
预测年份 [2024] 15.4亿美元
预测年份 [2030] 28.8亿美元
复合年增长率（%） 10.72%

市场动态：快速发展的爱迪生氏症药物市场的关键市场洞察

爱迪生氏症药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球爱迪生氏症症患者数量增加
    • 人们对肾上腺功能不全的认识不断提高
    • 建立坚实的医疗基础设施和优惠的报销政策
  • 市场限制因素
    • 艾迪生疗法相关的高成本
  • 市场机会
    • 对新一代技术整合先进疗法的需求不断增长
    • 活性化研发活动并提高各公司对爱迪生氏症药物开发的关注度
  • 市场挑战
    • 人们对爱迪生氏症缺乏认识

波特五力：驾驭爱迪生氏症药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解爱迪生氏症药物市场的外部影响

外部宏观环境因素在塑造爱迪生氏症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解爱迪生氏症治疗药物市场的竞争状况

对爱迪生氏症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

爱迪生氏症治疗药物市场中的 FPNV 定位矩阵供应商绩效评估

FPNV 定位矩阵是评估爱迪生氏症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为爱迪生氏症治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对爱迪生氏症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球爱迪生氏症发生率上升
      • 人们对肾上腺功能不全的认知不断增强
      • 引入强大的医疗基础设施和优惠的报销政策
    • 抑制因素
      • 艾迪生治疗相关的高成本
    • 机会
      • 对整合技术的新一代先进疗法的需求不断增长
      • 增加企业研发活动并专注于开发爱迪生氏症治疗方法
    • 任务
      • 人们对爱迪生氏症缺乏认识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的爱迪生氏症治疗药物市场

  • 糖皮质激素
    • 地塞米松
    • Hydrocortisone
    • 强的松
  • 盐皮质激素
    • ludrocortisone

第七章 依诊断分类的爱迪生氏症治疗药物市场

  • 影像检查
  • 临床检查

第八章爱迪生氏症治疗药物市场（依治疗）

  • 皮质类固醇注射
  • 自然疗法解决方案
  • 口服类固醇

第九章爱迪生氏症治疗药物市场：按分销管道

  • 电子商务
  • 医院药房
  • 零售药房

第 10 章爱迪生氏症治疗药物市场：依给药途径

  • 口服
  • 监护人

第十一章 美洲爱迪生氏症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区爱迪生氏症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲爱迪生氏症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Actiza Pharmaceutical Private Limited
  • Akorn Operating Company LLC
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bay Biosciences LLC
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt Ltd.
  • Cardinal Health, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • LUMITOS AG
  • Lupin Limited
  • Merck KGaA
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Recipharm AB
  • Sandoz International GmbH
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B16853776F01

The Addison's Disease Treatment Market was valued at USD 1.41 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 2.88 billion by 2030.

Addison's Disease, a rare endocrine disorder characterized by insufficient production of hormones by adrenal glands, creates a niche yet vital market for pharmaceutical treatments. The necessity for effective treatments arises from the disease's chronic nature and the essential role of hormone replacement therapies in preventing life-threatening adrenal crises. Currently, primary applications focus on corticosteroid and mineralocorticoid replacement therapies, with end-use finding significant traction in hospitals, specialty clinics, and home care settings, thanks to increasing patient awareness and advancements in telemedicine. Market growth is driven by factors such as rising prevalence of adrenal insufficiency disorders, improved diagnostic techniques, and a larger aged population at higher risk. Opportunities lie in the development of novel delivery mechanisms, such as implantable devices or extended-release formulations, improving patient compliance and quality of life. Additionally, ongoing research into genetic and biologic therapies presents an avenue for differentiated treatment offerings. However, the market faces limitations such as the high cost of R&D, potential side effects of long-term steroid use, and stringent regulatory approval processes that could delay new entrants. Challenges also include the need for increased awareness among healthcare providers for early diagnosis and treatment precision. Innovation in personalized medicine, leveraging genetic testing and AI-driven patient management systems, could significantly enhance treatment outcomes and market positioning. For business growth, strategic partnerships with research institutes and investment in bioinformatics may provide a competitive advantage. The nature of the Addison's Disease treatment market is competitive yet highly specialized, requiring strong scientific expertise and patient-centric approaches to succeed. Embracing digital health solutions and cultivating robust patient education initiatives stand out as strategic maneuvers to navigate the evolving landscape and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 1.41 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 2.88 billion
CAGR (%) 10.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Addison's Disease Treatment Market

The Addison's Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of Addison's disease globally
    • Growing awareness regarding adrenal insufficiency
    • Inception of robust healthcare infrastructure and favorable reimbursement policies
  • Market Restraints
    • High costs associated with the Addison treatment medications
  • Market Opportunities
    • Growing demand for new generation technologically integrated advanced therapeutic drugs
    • Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
  • Market Challenges
    • Lack of awareness among people regarding Addison's disease

Porter's Five Forces: A Strategic Tool for Navigating the Addison's Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Addison's Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Addison's Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Addison's Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Addison's Disease Treatment Market

A detailed market share analysis in the Addison's Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Addison's Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Addison's Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Addison's Disease Treatment Market

A strategic analysis of the Addison's Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Addison's Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Actiza Pharmaceutical Private Limited, Akorn Operating Company LLC, Amgen Inc., Amneal Pharmaceuticals, Inc., Bay Biosciences LLC, Bayer AG, Bio-Techne Corporation, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt Ltd., Cardinal Health, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, LUMITOS AG, Lupin Limited, Merck KGaA, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., Recipharm AB, Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Addison's Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Glucocorticoid and Mineralocorticoid. The Glucocorticoid is further studied across Dexamethasone, Hydrocortisone, and Prednisone. The Mineralocorticoid is further studied across Fludrocortisone.
  • Based on Diagnosis, market is studied across Imaging Testing and Laboratory Testing.
  • Based on Treatments, market is studied across Corticosteroid Injections, Naturopathic Solutions, and Oral Corticosteroids.
  • Based on Distribution Channel, market is studied across E-Commerce, Hospital Pharmacy, and Retail Pharmacy.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Addison's disease globally
      • 5.1.1.2. Growing awareness regarding adrenal insufficiency
      • 5.1.1.3. Inception of robust healthcare infrastructure and favorable reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the Addison treatment medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for new generation technologically integrated advanced therapeutic drugs
      • 5.1.3.2. Increasing R&D activities and rising focus of the companies in developing treatments for Addison's disease
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness among people regarding Addison's disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Addison's Disease Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Glucocorticoid
    • 6.2.1. Dexamethasone
    • 6.2.2. Hydrocortisone
    • 6.2.3. Prednisone
  • 6.3. Mineralocorticoid
    • 6.3.1. Fludrocortisone

7. Addison's Disease Treatment Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Imaging Testing
  • 7.3. Laboratory Testing

8. Addison's Disease Treatment Market, by Treatments

  • 8.1. Introduction
  • 8.2. Corticosteroid Injections
  • 8.3. Naturopathic Solutions
  • 8.4. Oral Corticosteroids

9. Addison's Disease Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. E-Commerce
  • 9.3. Hospital Pharmacy
  • 9.4. Retail Pharmacy

10. Addison's Disease Treatment Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
  • 10.3. Parental

11. Americas Addison's Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Addison's Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Addison's Disease Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Actiza Pharmaceutical Private Limited
  • 3. Akorn Operating Company LLC
  • 4. Amgen Inc.
  • 5. Amneal Pharmaceuticals, Inc.
  • 6. Bay Biosciences LLC
  • 7. Bayer AG
  • 8. Bio-Techne Corporation
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. BTL Biotechno Labs Pvt Ltd.
  • 13. Cardinal Health, Inc.
  • 14. Eli Lilly and Company
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. LUMITOS AG
  • 18. Lupin Limited
  • 19. Merck KGaA
  • 20. Neurocrine Biosciences, Inc.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Recipharm AB
  • 24. Sandoz International GmbH
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ADDISON'S DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ADDISON'S DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ADDISON'S DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ADDISON'S DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADDISON'S DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADDISON'S DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY FLUDROCORTISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY IMAGING TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY NATUROPATHIC SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 161. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 174. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 176. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 183. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 190. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 197. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 204. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 211. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 218. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 225. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 232. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 239. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 245. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 246. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 252. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 253. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 260. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 274. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 281. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 288. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 294. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 295. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 301. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 302. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 303. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 307. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY GLUCOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 309. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY MINERALOCORTICOID, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES ADDISON'S DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED KINGDOM